Emily C L Wong
McMaster University
EpidemiologyInterquartile rangeInternal medicineLogistic regressionOdds ratioRandomized controlled trialProspective cohort studyHazard ratioInfliximabInflammatory bowel diseaseUstekinumabDiseaseCrohn's diseaseUlcerative colitisKidney cancerConfidence intervalClinical trialPost-hoc analysisMedicineCohortGastroenterology
28Publications
2H-index
24Citations
Publications 31
Newest
#1Emily C L Wong (McMaster University)H-Index: 2
#2Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 164
Last. Neeraj Narula (McMaster University)H-Index: 23
view all 7 authors...
Source
#1Neeraj Narula (McMaster University)H-Index: 23
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Walter Reinisch (Medical University of Vienna)H-Index: 100
view all 6 authors...
Background & Aims null Comparative effectiveness studies are needed to help position therapies for ulcerative colitis (UC). We compared the efficacy of infliximab vs vedolizumab for moderate to severe biologic-naive UC using patient-level data from clinical trial program data sets. null null null Methods null This was a post hoc analysis of 3 UC clinical trial programs that included data on 795 biologic-naive UC patients. Differences in proportions of patients achieving week 6 clinical remission...
Source
#1Neeraj Narula (Population Health Research Institute)H-Index: 23
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Ravi Prasad VarmaH-Index: 10
view all 35 authors...
OBJECTIVE To evaluate the relation between intake of ultra-processed food and risk of inflammatory bowel disease (IBD). DESIGN Prospective cohort study. SETTING 21 low, middle, and high income countries across seven geographical regions (Europe and North America, South America, Africa, Middle East, south Asia, South East Asia, and China). PARTICIPANTS 116 087 adults aged 35-70 years with at least one cycle of follow-up and complete baseline food frequency questionnaire (FFQ) data (country specif...
Source
#1Neeraj Narula (McMaster University)H-Index: 23
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 29
view all 7 authors...
Abstract null null Background & Aims null The prognostic value of histologic scores, grades, and individual histologic sub-components, alone or in combination with endoscopy, for predicting endoscopic improvement (EI) and histo-endoscopic mucosal improvement (HEMI) during maintenance therapy in ulcerative colitis (UC) remains uncertain. null null null Methods null Post-hoc analysis of participants from the VARSITY trial (n=734 with histology). Receiver operating characteristic and multi-variate ...
Source
#1Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 29
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Neeraj Narula (McMaster University)H-Index: 23
view all 4 authors...
Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clinical decision support tools for achieving clinical remission (CREM) with vedolizumab and ustekinumab in CD.1-4 We now aim to develop a clinical decision support tool for infliximab in CD.
Source
#1Neeraj Narula (Population Health Research Institute)H-Index: 23
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Salim Yusuf (Population Health Research Institute)H-Index: 247
view all 6 authors...
Source
#1Neeraj Narula (McMaster University)H-Index: 23
#2Achuthan Aruljothy (McMaster University)H-Index: 3
Last. Walter Reinisch (Medical University of Vienna)H-Index: 100
view all 7 authors...
This post hoc analysis of the UNITI studies found ustekinumab (UST) did not significantly improve overall extraintestinal manifestations (EIMs) of Crohn's disease compared to placebo-treated patients at weeks 6 and 52. BACKGROUND AND AIMS The UNITI trials demonstrated that UST was effective in inducing and maintaining clinical remission in Crohn's disease (CD). However, limited data exists regarding its effectiveness for treatment of EIMs. This post hoc analysis evaluated the efficacy of UST in ...
2 CitationsSource
Source
Source
#1Neeraj Narula (McMaster University)H-Index: 23
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Mark S. Silverberg (Mount Sinai Hospital)H-Index: 76
view all 8 authors...
BACKGROUND AND AIMS Crohn's disease (CD) patients who previously failed anti-TNF therapy are at higher risk of treatment failure with subsequent biologics. This study aims to determine the effectiveness and safety of higher maintenance dose regimens of adalimumab compared to standard doses in CD patients who failed anti-TNF. METHODS In this retrospective observational study, CD patients who failed anti-TNF and received adalimumab were categorized according to their post-induction maintenance reg...
Source